Alzheimer's Biomarker Testing Coverage

Summary#

This bill requires private group and individual health plans and state Medicaid programs to cover testing that looks for biomarkers of Alzheimer’s disease. The testing must be covered when used for early detection, diagnosis, treatment decisions, risk stratification, management, or monitoring of Alzheimer’s disease and when it fits FDA labeling, Medicare coverage rules, or clinical guidance. The bill also sets rules on cost-sharing, prior authorization timing, and limits on step therapy, and it directs the NIH to contract with the National Academies to study the value of biomarker testing.

• Main change: Requires coverage of “Alzheimer's biomarker testing” by group health plans, individual policies, and Medicaid.
• Coverage rules: No special extra cost-sharing or stricter treatment limits than for other medical/surgical benefits; no step therapy; prompt prior authorization decisions (72 hours, or 24 hours if delay risks health), and automatic approval if the insurer misses the deadline.
• Definition: “Alzheimer's biomarker testing” includes analysis of tissue, blood, or other biospecimens and covers single tests, panels, protein tests, and whole genome/exome/transcriptome sequencing when used for specified Alzheimer’s purposes and consistent with FDA labeling, Medicare national coverage, or clinical guidance.
• Equity and method: Benefits must be provided to promote equitable access, including for rural and underserved areas, and support minimally invasive testing when appropriate.
• Timing and study: Private plan rules start for plan years beginning one year after enactment; Medicaid rules start for calendar quarters one year after enactment. NIH must commission a study/report within 1 year and annually for the next 2 years on the value of biomarker testing.

What it means for you#

• People with private employer plans or individual plans

  • You must be offered coverage for Alzheimer’s biomarker testing when it meets the bill’s purposes and criteria.
  • Your cost-sharing for these tests cannot be more restrictive than your plan’s usual medical/surgical cost-sharing. Plans may not add special extra copays just for these tests.
  • If your doctor needs prior authorization for a test, the plan must decide in 72 hours, or 24 hours for urgent cases; missing the deadline means the request is treated as approved.
  • Plans cannot require step therapy (trying other options first) before approving these tests.

• Medicaid enrollees

  • State Medicaid programs must cover the same Alzheimer’s biomarker testing and follow the same coverage rules as private plans.
  • Coverage takes effect starting with calendar quarters one year after the bill becomes law.

• Health care providers and labs

  • More patients may get orders for biomarker tests that insurance must cover.
  • Providers may get faster prior authorization decisions due to the 72/24-hour deadlines.
  • Labs that run molecular or genomic tests could see higher demand, including for broader sequencing tests that the bill includes.

• Rural and underserved communities

  • The bill requires benefits be provided in a way that promotes equitable access; this could mean more attention to offering minimally invasive tests and to reach in underserved areas. The bill does not set specific programs or funding for outreach or infrastructure.

• Researchers and federal agencies

  • The NIH must hire the National Academies to study and report on the value of biomarker testing within one year, then annually for two more years.

Expenses#

No publicly available information.

• The bill itself does not include a fiscal estimate or cost numbers.
• Likely areas of cost or administrative change (not estimated in the bill):
  • Increased medical spending for insurers and Medicaid to pay for more biomarker tests.
  • Administrative costs for insurers to update coverage rules, implement faster prior authorization processes, and remove step-therapy rules.
  • Costs for labs to expand capacity or comply with demand, especially for complex genomic tests.
  • Cost to NIH to contract with the National Academies for the required study and reports (amount not specified).
• The bill does not specify whether federal Medicaid matching rules change or whether there is extra federal funding to help states cover increased testing demand.

Proponents' View#

• The bill appears intended to expand access to testing that can detect or inform treatment of Alzheimer’s disease earlier.
• Supporters may argue this could help people learn their Alzheimer’s risk sooner, identify who may be eligible for FDA-approved treatments, and improve treatment selection and monitoring.
• The prior authorization deadlines and auto-approval rule are meant to speed patient access to testing.
• Requiring parity in cost-sharing and banning step therapy for these tests aims to reduce financial and administrative barriers.
• Requiring equity and a preference for minimally invasive testing could improve access for rural and underserved populations.

Opponents' View#

• One concern is cost: mandatory coverage could increase short-term spending for private insurers and Medicaid, but the bill gives no cost estimates or funding to states.
• The bill’s definition of biomarker testing is broad and includes whole genome/exome/transcriptome sequencing. This may raise questions about privacy, handling of genetic information, and incidental findings. The bill does not set rules for data use or protections beyond coverage.
• The bill does not limit how often or under what precise clinical scenarios tests may be ordered beyond referring to FDA labeling, Medicare coverage, or clinical guidance; this could allow wide use without clear clinical limits.
• Faster prior authorization timelines (72/24 hours) may be difficult for some insurers or providers to meet and could create administrative strain.
• It is unclear how “clinical practice guidelines” or “consensus statements” will be identified in practice and which organizations’ guidelines will count. The bill requires those documents be developed independently with conflict-of-interest policies, but it does not name who will make those calls.
• The bill requires NIH to commission a study, but it does not delay the coverage mandate until after the study, so coverage would start before the study’s findings are available.